Although the 5-FU treatment could effectively inhibit colorectal tumor growth, we observed an enrichment of CSCs in 5-FU-treated tumors supported by the upregulation of CSC markers (CD44, SOX2), which could be responsible for the observed chemoresistance. Here, CD44 is linked to colorectal neoplasm.